Surgical management of late relapse on surveillance in patients presenting with clinical stage i testicular cancer

Kevin R. Rice, Stephen D W Beck, Jose A. Pedrosa, Timothy Masterson, Lawrence Einhorn, Richard Foster

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective To determine survival outcomes in clinical stage I germ cell tumor (GCT) patients requiring retroperitoneal lymph node dissection (RPLND) for late relapse (LR) occurring while on surveillance. Methods The Indiana University Testis Cancer Database was queried from 1985 to 2013 to identify all patients who presented with clinical stage I GCT, elected surveillance, relapsed ≥2 years after initial diagnosis, and underwent RPLND in treatment of their LR. Clinical, pathologic, and treatment characteristics were reviewed. Results Twenty-eight patients met inclusion criteria. The mean age at diagnosis was 29.3 years. Testicular primary was pure seminoma in 2, intratubular germ cell neoplasia with scar in 1, nonseminomatous GCT in 24, and unknown in 1 patient. The median time from diagnosis to relapse was 48.5 months (range, 28-321 months). At relapse, serum tumor markers were elevated in 13 patients (46.4%). Nineteen patients were given cisplatin-based chemotherapy at LR. RPLND was initial management of LR in 9. At RPLND, 10, 5, and 13 patients demonstrated fibrosis, teratoma, and viable malignancy, respectively. On the last follow-up, 24 patients (85.7%) were free of disease and 4 patients (14.3%) had died of their disease. Conclusion When examining outcomes among patients undergoing RPLND at LR of GCT, it appears that patients experiencing LR on surveillance have more favorable histology and survival outcomes than previously reported for unselected patients experiencing LR.

Original languageEnglish
Pages (from-to)886-890
Number of pages5
JournalUrology
Volume84
Issue number4
DOIs
StatePublished - Oct 1 2014

Fingerprint

Testicular Neoplasms
Recurrence
Lymph Node Excision
Germ Cell and Embryonal Neoplasms
Seminoma
Survival
Teratoma
Tumor Biomarkers
Germ Cells
Cisplatin
Cicatrix
Neoplasms
Histology
Fibrosis
Biomarkers
Databases

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Surgical management of late relapse on surveillance in patients presenting with clinical stage i testicular cancer. / Rice, Kevin R.; Beck, Stephen D W; Pedrosa, Jose A.; Masterson, Timothy; Einhorn, Lawrence; Foster, Richard.

In: Urology, Vol. 84, No. 4, 01.10.2014, p. 886-890.

Research output: Contribution to journalArticle

@article{1ae30cedb25c44088cc3027fa25bd4e9,
title = "Surgical management of late relapse on surveillance in patients presenting with clinical stage i testicular cancer",
abstract = "Objective To determine survival outcomes in clinical stage I germ cell tumor (GCT) patients requiring retroperitoneal lymph node dissection (RPLND) for late relapse (LR) occurring while on surveillance. Methods The Indiana University Testis Cancer Database was queried from 1985 to 2013 to identify all patients who presented with clinical stage I GCT, elected surveillance, relapsed ≥2 years after initial diagnosis, and underwent RPLND in treatment of their LR. Clinical, pathologic, and treatment characteristics were reviewed. Results Twenty-eight patients met inclusion criteria. The mean age at diagnosis was 29.3 years. Testicular primary was pure seminoma in 2, intratubular germ cell neoplasia with scar in 1, nonseminomatous GCT in 24, and unknown in 1 patient. The median time from diagnosis to relapse was 48.5 months (range, 28-321 months). At relapse, serum tumor markers were elevated in 13 patients (46.4{\%}). Nineteen patients were given cisplatin-based chemotherapy at LR. RPLND was initial management of LR in 9. At RPLND, 10, 5, and 13 patients demonstrated fibrosis, teratoma, and viable malignancy, respectively. On the last follow-up, 24 patients (85.7{\%}) were free of disease and 4 patients (14.3{\%}) had died of their disease. Conclusion When examining outcomes among patients undergoing RPLND at LR of GCT, it appears that patients experiencing LR on surveillance have more favorable histology and survival outcomes than previously reported for unselected patients experiencing LR.",
author = "Rice, {Kevin R.} and Beck, {Stephen D W} and Pedrosa, {Jose A.} and Timothy Masterson and Lawrence Einhorn and Richard Foster",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.urology.2014.05.054",
language = "English",
volume = "84",
pages = "886--890",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Surgical management of late relapse on surveillance in patients presenting with clinical stage i testicular cancer

AU - Rice, Kevin R.

AU - Beck, Stephen D W

AU - Pedrosa, Jose A.

AU - Masterson, Timothy

AU - Einhorn, Lawrence

AU - Foster, Richard

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Objective To determine survival outcomes in clinical stage I germ cell tumor (GCT) patients requiring retroperitoneal lymph node dissection (RPLND) for late relapse (LR) occurring while on surveillance. Methods The Indiana University Testis Cancer Database was queried from 1985 to 2013 to identify all patients who presented with clinical stage I GCT, elected surveillance, relapsed ≥2 years after initial diagnosis, and underwent RPLND in treatment of their LR. Clinical, pathologic, and treatment characteristics were reviewed. Results Twenty-eight patients met inclusion criteria. The mean age at diagnosis was 29.3 years. Testicular primary was pure seminoma in 2, intratubular germ cell neoplasia with scar in 1, nonseminomatous GCT in 24, and unknown in 1 patient. The median time from diagnosis to relapse was 48.5 months (range, 28-321 months). At relapse, serum tumor markers were elevated in 13 patients (46.4%). Nineteen patients were given cisplatin-based chemotherapy at LR. RPLND was initial management of LR in 9. At RPLND, 10, 5, and 13 patients demonstrated fibrosis, teratoma, and viable malignancy, respectively. On the last follow-up, 24 patients (85.7%) were free of disease and 4 patients (14.3%) had died of their disease. Conclusion When examining outcomes among patients undergoing RPLND at LR of GCT, it appears that patients experiencing LR on surveillance have more favorable histology and survival outcomes than previously reported for unselected patients experiencing LR.

AB - Objective To determine survival outcomes in clinical stage I germ cell tumor (GCT) patients requiring retroperitoneal lymph node dissection (RPLND) for late relapse (LR) occurring while on surveillance. Methods The Indiana University Testis Cancer Database was queried from 1985 to 2013 to identify all patients who presented with clinical stage I GCT, elected surveillance, relapsed ≥2 years after initial diagnosis, and underwent RPLND in treatment of their LR. Clinical, pathologic, and treatment characteristics were reviewed. Results Twenty-eight patients met inclusion criteria. The mean age at diagnosis was 29.3 years. Testicular primary was pure seminoma in 2, intratubular germ cell neoplasia with scar in 1, nonseminomatous GCT in 24, and unknown in 1 patient. The median time from diagnosis to relapse was 48.5 months (range, 28-321 months). At relapse, serum tumor markers were elevated in 13 patients (46.4%). Nineteen patients were given cisplatin-based chemotherapy at LR. RPLND was initial management of LR in 9. At RPLND, 10, 5, and 13 patients demonstrated fibrosis, teratoma, and viable malignancy, respectively. On the last follow-up, 24 patients (85.7%) were free of disease and 4 patients (14.3%) had died of their disease. Conclusion When examining outcomes among patients undergoing RPLND at LR of GCT, it appears that patients experiencing LR on surveillance have more favorable histology and survival outcomes than previously reported for unselected patients experiencing LR.

UR - http://www.scopus.com/inward/record.url?scp=84921967970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921967970&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2014.05.054

DO - 10.1016/j.urology.2014.05.054

M3 - Article

VL - 84

SP - 886

EP - 890

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -